- Home
- USGO vs ACHV Comparison
USGO vs ACHV Comparison
Compare USGO & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USGO
- ACHV
- Stock Information
- Founded
- USGO 2015
- ACHV N/A
- Country
- USGO United States
- ACHV United States
- Employees
- USGO N/A
- ACHV N/A
- Industry
- USGO Precious Metals
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- USGO Basic Materials
- ACHV Health Care
- Exchange
- USGO Nasdaq
- ACHV Nasdaq
- Market Cap
- USGO 117.3M
- ACHV 131.3M
- IPO Year
- USGO 2023
- ACHV N/A
- Fundamental
- Price
- USGO $9.57
- ACHV $3.08
- Analyst Decision
- USGO Strong Buy
- ACHV Strong Buy
- Analyst Count
- USGO 2
- ACHV 2
- Target Price
- USGO $26.50
- ACHV $16.00
- AVG Volume (30 Days)
- USGO 81.6K
- ACHV 1.6M
- Earning Date
- USGO 11-12-2025
- ACHV 11-06-2025
- Dividend Yield
- USGO N/A
- ACHV N/A
- EPS Growth
- USGO N/A
- ACHV N/A
- EPS
- USGO N/A
- ACHV N/A
- Revenue
- USGO N/A
- ACHV N/A
- Revenue This Year
- USGO N/A
- ACHV N/A
- Revenue Next Year
- USGO N/A
- ACHV N/A
- P/E Ratio
- USGO N/A
- ACHV N/A
- Revenue Growth
- USGO N/A
- ACHV N/A
- 52 Week Low
- USGO $5.25
- ACHV $1.84
- 52 Week High
- USGO $14.46
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- USGO 62.11
- ACHV 56.04
- Support Level
- USGO $8.82
- ACHV $2.68
- Resistance Level
- USGO $9.68
- ACHV $3.30
- Average True Range (ATR)
- USGO 0.59
- ACHV 0.25
- MACD
- USGO 0.08
- ACHV 0.02
- Stochastic Oscillator
- USGO 87.22
- ACHV 49.38
About USGO U.S. GoldMining Inc. Common stock
US Goldmining Inc is a mineral exploration and development company. It is focused on the exploration and development of a project located in Alaska, USA. The company's sole property is Whistler Project which is a gold-copper exploration project located in the Yentna Mining District, approximately 170 km northwest of Anchorage, Alaska.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.